Abbott Laboratories (ABT)
|Net Income (ttm)||6.38B|
|Ex-Dividend Date||Oct 14, 2021|
|Day's Range||123.09 - 125.60|
|52-Week Range||101.56 - 129.20|
|Price Target||134.28 (+7.4%)|
|Est. Earnings Date||n/a|
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidi... [Read more...]
In 2020, ABT's revenue was $34.61 billion, an increase of 8.48% compared to the previous year's $31.90 billion. Earnings were $4.50 billion, an increase of 21.91%.Financial Statements
According to 24 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is 134.28, which is an increase of 7.38% from the latest price.
There was nothing but good news for Abbott in Q3.
All four of the company's divisions posted strong growth, but one in particular was a standout.
On Wednesday, Abbott Laboratories (NYSE:ABT) shares surged nearly 4% after announcing solid fiscal third-quarter results. The company reported its most recent quarterly revenue and earnings before marke...
Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Just before Tuesday's close, Netflix (NASDAQ: NFLX) reported better-than-expected earnings by adding 4.4 million subscribers in the third quarter. The company cited a robust slate of content including t...
Abbott (ABT) delivered earnings and revenue surprises of 52.17% and 15.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Abbott Laboratories (NYSE: ABT) is trading higher Wednesday after the company announced better-than-expected third-quarter financial results and raised guidance. Abbott reported quarterly earnings of $...
Abbott Laboratories (NYSE: ABT) reported a 70.5% rise in quarterly profit to $2.1 billion, helped by strength in its medical devices and diagnostics businesses due to a rebound in COVID-19 test sales am...
(Reuters) -Abbott Laboratories raised its full-year adjusted earnings forecast after reporting a rise in quarterly profit, driven by strength in its mainstay businesses and a rebound in COVID-19 test sa...
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
ABBOTT PARK, Ill., Oct. 20, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept.
Abbott Laboratories(NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2021-10-20. Here's what investors need to know before the announcement.
Abbott is scheduled to report its Q3 2021 results on Wednesday, October 20, and we expect it to be slightly above the consensus estimates, driven by a rise in demand for medical devices as well as its e...
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
In the latest trading session, Abbott (ABT) closed at $117.57, marking a +0.49% move from the previous day.
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.
White House pushes back on Abbott's executive order
CNBC's Seema Mody reports on the Biden administration's response to Texas Gov. Abbott's ban of vaccine mandates among employers in the state.
Abbott President & CEO Robert Ford on revolutionizing COVID-19 at-home testing technology
On this episode of Yahoo Finance Presents, Abbott President & CEO Robert Ford, sat down with Yahoo Finance's Anjalee Khemlani to discuss Abbott's upcoming keynote address at CES 2022 and COVID-19 test p...
In the latest trading session, Abbott (ABT) closed at $117.91, marking a +1.22% move from the previous day.
Abbott Labs CEO on demand for Covid-19 tests amid delta variant
Abbott Laboratories CEO Robert Ford joins 'TechCheck' to explain why he's confident the company can supply Covid-19 testing to meet demand and whether Abbott is considering investing in AI software.
The Amplatzer Talisman PFO Occlusion System from Abbott (ABT) is used to treat patients with a patent foramen ovale and are at risk of recurrent ischemic stroke.